{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:15:11Z","timestamp":1783646111457,"version":"3.55.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Jiangsu Pharmaceutical Society-Aosaikang Hospital Pharmaceutical Research Fund","award":["No.A202202"],"award-info":[{"award-number":["No.A202202"]}]},{"name":"Research Project of Jiangsu Cancer Hospital","award":["No.ZG202203"],"award-info":[{"award-number":["No.ZG202203"]}]},{"DOI":"10.13039\/501100014764","name":"China International Medical Foundation","doi-asserted-by":"publisher","award":["Z-2021-46-2101-2023"],"award-info":[{"award-number":["Z-2021-46-2101-2023"]}],"id":[{"id":"10.13039\/501100014764","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-026-14618-8","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T19:04:41Z","timestamp":1779131081000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness analysis of the treatment pathway after trastuzumab treatment failure in patients with HER2-positive advanced breast cancer: a chinese health system perspective"],"prefix":"10.1186","volume":"26","author":[{"given":"Tianqi","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenlu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"issue":"6","key":"14618_CR1","first-page":"439","volume":"67","author":"CE DeSantis","year":"2017","unstructured":"DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017;67(6):439\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"14618_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"4785","key":"14618_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science. 1987;235(4785):177\u201382.","journal-title":"Science"},{"issue":"2","key":"14618_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/35052073","volume":"2","author":"Y Yarden","year":"2001","unstructured":"Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127\u201337.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"8","key":"14618_CR5","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1200\/JCO.1997.15.8.2894","volume":"15","author":"MF Press","year":"1997","unstructured":"Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, et al. HER-2\/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997;15(8):2894\u2013904.","journal-title":"J Clin Oncol"},{"issue":"1","key":"14618_CR6","doi-asserted-by":"publisher","first-page":"100343","DOI":"10.1016\/j.esmoop.2021.100343","volume":"7","author":"G Nader-Marta","year":"2022","unstructured":"Nader-Marta G, Martins-Branco D, de Azambuja, EJEo. How we treat patients with metastatic HER2-positive breast cancer. ESMO Open. 2022;7(1):100343.","journal-title":"ESMO Open"},{"issue":"10087","key":"14618_CR7","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","volume":"389","author":"S Loibl","year":"2017","unstructured":"Loibl S, Gianni LJTL. HER2-positive breast cancer. Lancet. 2017;389(10087):2415\u201329.","journal-title":"Lancet"},{"issue":"4","key":"14618_CR8","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1002\/jcp.29216","volume":"235","author":"A Derakhshani","year":"2020","unstructured":"Derakhshani A, Rezaei Z, Safarpour H, Sabri M, Mir A, Sanati MA, et al. Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy. J Cell Physiol. 2020;235(4):3142\u201356.","journal-title":"J Cell Physiol"},{"issue":"18","key":"14618_CR9","doi-asserted-by":"publisher","first-page":"4543","DOI":"10.3390\/cancers14184543","volume":"14","author":"M Gamez-Chiachio","year":"2022","unstructured":"Gamez-Chiachio M, Sarri\u00f3 D, Moreno-Bueno GJC. Novel therapies and strategies to overcome resistance to anti-HER2-targeted drugs. Cancers (Basel). 2022;14(18):4543.","journal-title":"Cancers (Basel)"},{"issue":"19","key":"14618_CR10","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1002\/cncr.33102","volume":"126","author":"S Kunte","year":"2020","unstructured":"Kunte S, Abraham J, Montero AJJC. Novel HER2\u2013targeted therapies for HER2\u2013positive metastatic breast cancer. Cancer. 2020;126(19):4278\u201388.","journal-title":"Cancer"},{"issue":"5","key":"14618_CR11","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.3390\/ijms20051115","volume":"20","author":"G Rinnerthaler","year":"2019","unstructured":"Rinnerthaler G, Gampenrieder SP, Greil R. HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer. Int J Mol Sci. 2019;20(5):1115. Epub 2019\/03\/08.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"14618_CR12","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1158\/2159-8290.CD-20-1265","volume":"12","author":"CA Chang","year":"2022","unstructured":"Chang CA, Jen J, Jiang S, Sayad A, Mer AS, Brown KR, et al. Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2\u2009+\u2009Breast Cancer. Cancer Discov. 2022;12(4):1022\u201345.","journal-title":"Cancer Discov"},{"issue":"26","key":"14618_CR13","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733\u201343.","journal-title":"N Engl J Med"},{"key":"14618_CR14","doi-asserted-by":"crossref","unstructured":"Yan M, Bian L, Hu X, Zhang Q, Ouyang Q, Feng J et al. Pyrotinib plus capecitabine for human epidermal factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study. Transl Breast Cancer Res. 2020;1.","DOI":"10.21037\/tbcr-20-25"},{"key":"14618_CR15","volume-title":"CSCO Breast Cancer Guidelines 2023","author":"Chinese Society of Clinical Oncology (CSCO)","year":"2023","unstructured":"Chinese Society of Clinical Oncology (CSCO). CSCO Breast Cancer Guidelines 2023. Beijing: People\u2019s Medical Publishing House; 2023."},{"key":"14618_CR16","doi-asserted-by":"publisher","first-page":"1119906","DOI":"10.3389\/fphar.2023.1119906","volume":"14","author":"X Chen","year":"2023","unstructured":"Chen X, Zhao M, Tian L. Economic evaluation of five first-line PD-(L)1 inhibitors for treating non-squamous non-small cell lung cancer in China: A cost-effectiveness analysis based on network meta-analysis. Front Pharmacol. 2023;14:1119906.","journal-title":"Front Pharmacol"},{"key":"14618_CR17","unstructured":"Woods B, Sideris E, Palmer S, Latimer N, Soares M. NICE DSU technical support document 19: partitioned survival analysis for decision modelling in. 2017."},{"issue":"3","key":"14618_CR18","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s41669-021-00263-w","volume":"5","author":"G Ball","year":"2021","unstructured":"Ball G, Levine M, Thabane L, Tarride JE. Onwards and Upwards: A Systematic Survey of Economic Evaluation Methods in Oncology. Pharmacoecon Open. 2021;5(3):397\u2013410.","journal-title":"Pharmacoecon Open"},{"issue":"3","key":"14618_CR19","doi-asserted-by":"publisher","first-page":"544","DOI":"10.5114\/aoms.2015.52356","volume":"11","author":"T Qin","year":"2015","unstructured":"Qin T, Yuan ZY, Peng RJ, Bai B, Zeng YD, Shi YX, et al. Clinicopathologic characteristics and prognostic factors for HER2-positive patients with metastatic breast cancer in southern China. Arch Med Sci. 2015;11(3):544\u201350.","journal-title":"Arch Med Sci"},{"issue":"7","key":"14618_CR20","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.3390\/cancers16071255","volume":"16","author":"R Weide","year":"2024","unstructured":"Weide R, Feiten S, Wassmann C, Rendenbach B, Braun U, Burkhard O, et al. Metastatic Breast Cancer: Prolonging Life in Routine Oncology Care. Cancers (Basel). 2024;16(7):1255.","journal-title":"Cancers (Basel)"},{"key":"14618_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vhri.2020.07.580","volume":"24","author":"X Yue","year":"2021","unstructured":"Yue X, Li Y, Wu J, Guo JJ. Current Development and Practice of Pharmacoeconomic Evaluation Guidelines for Universal Health Coverage in China. Value Health Reg Issues. 2021;24:1\u20135.","journal-title":"Value Health Reg Issues"},{"key":"14618_CR22","unstructured":"Edejer TT-T, Edejer TT-T. Making choices in health: WHO guide to cost-effectiveness analysis. World Health Organization; 2003."},{"key":"14618_CR23","unstructured":"National Bureau of Statistics of China. National Data. https:\/\/data.stats.gov.cn\/index.htm."},{"issue":"19","key":"14618_CR24","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783\u201391.","journal-title":"N Engl J Med"},{"issue":"6","key":"14618_CR25","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","volume":"18","author":"V Di\u00e9ras","year":"2017","unstructured":"Di\u00e9ras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(6):732\u201342.","journal-title":"Lancet Oncol"},{"issue":"29","key":"14618_CR26","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1200\/JCO.19.00108","volume":"37","author":"F Ma","year":"2019","unstructured":"Ma F, Ouyang Q, Li W, Jiang Z, Tong Z, Liu Y, et al. Pyrotinib or lapatinib combined with capecitabine in HER2\u2013positive metastatic breast cancer with prior taxanes, anthracyclines, and\/or trastuzumab: A randomized, phase II study. J Clin Oncol. 2019;37(29):2610\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"14618_CR27","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S1470-2045(20)30702-6","volume":"22","author":"B Xu","year":"2021","unstructured":"Xu B, Yan M, Ma F, Hu X, Feng J, Ouyang Q, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(3):351\u201360.","journal-title":"Lancet Oncol"},{"issue":"10371","key":"14618_CR28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","volume":"401","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401(10371):105\u201317.","journal-title":"Lancet"},{"issue":"12","key":"14618_CR29","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s J, Kim S-B, Chung W-P, Im S-A, Park YH, Hegg R, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386(12):1143\u201354.","journal-title":"N Engl J Med"},{"key":"14618_CR30","unstructured":"State Council Information Office of the People\u2019s Republic of China. Report on Nutrition and chronic disease status of chinese residents. 2020. https:\/\/www.chinanutri.cn\/yyjkzxpt\/yyjkkpzx\/yytsg\/2020\/."},{"issue":"10","key":"14618_CR31","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1007\/s12325-022-02273-4","volume":"39","author":"J Wang","year":"2022","unstructured":"Wang J, Yi Y, Wan X, Zeng X, Peng Y, Tan C. Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA. Adv Ther. 2022;39(10):4583\u201393.","journal-title":"Adv Ther"},{"issue":"1","key":"14618_CR32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1):9.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"14618_CR33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1471-2288-11-61","volume":"11","author":"JP Jansen","year":"2011","unstructured":"Jansen JP. Network meta-analysis of survival data with fractional polynomials. BMC Med Res Methodol. 2011;11(1):61.","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"14618_CR34","doi-asserted-by":"publisher","first-page":"700","DOI":"10.3390\/nu13020700","volume":"13","author":"ME Andreu-Rein\u00f3n","year":"2021","unstructured":"Andreu-Rein\u00f3n ME, Chirlaque MD, Gavrila D, Amiano P, Mar J, Tainta M, et al. Mediterranean diet and risk of dementia and Alzheimer\u2019s disease in the EPIC-Spain dementia cohort study. Nutrients. 2021;13(2):700.","journal-title":"Nutrients"},{"key":"14618_CR35","unstructured":"International Monetary Fund. International financial statistics. https:\/\/www.imf.org\/en\/publications\/international-financial-statistics\/issues\/2016\/12\/31\/international-financial-statistics-20151"},{"issue":"2","key":"14618_CR36","first-page":"e12965","volume":"28","author":"S Li","year":"2019","unstructured":"Li S, Wang M, Liu L, Chen GJE. Which approach is better in eliciting health state utilities from breast cancer patients? Evidence from mainland China. Eur J Cancer Care (Engl). 2019;28(2):e12965.","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"2","key":"14618_CR37","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s10549-012-2268-1","volume":"136","author":"Y Bai","year":"2012","unstructured":"Bai Y, Ye M, Cao H, Ma X, Xu Y, Wu B. Economic evaluation of radiotherapy for early breast cancer after breast-conserving surgery in a health resource-limited setting. Breast Cancer Res Treat. 2012;136(2):547\u201357.","journal-title":"Breast Cancer Res Treat"},{"issue":"40","key":"14618_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta11400","volume":"11","author":"S Ward","year":"2007","unstructured":"Ward S, Simpson E, Davis S, Hind D, Rees A, Wilkinson A. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. Health Technol Assess. 2007;11(40):1\u2013144.","journal-title":"Health Technol Assess"},{"key":"14618_CR39","unstructured":"Yao ZH. The big data service platform for China\u2019s health industry: information query of drug bid winning. https:\/\/data.yaozh.com\/"},{"issue":"4","key":"14618_CR40","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1200\/JCO.19.01525","volume":"38","author":"J Jayasekera","year":"2020","unstructured":"Jayasekera J, Mandelblatt JS. Systematic Review of the Cost Effectiveness of Breast Cancer Prevention, Screening, and Treatment Interventions. J Clin Oncol. 2020;38(4):332\u201350.","journal-title":"J Clin Oncol"},{"issue":"11","key":"14618_CR41","doi-asserted-by":"publisher","first-page":"e040691","DOI":"10.1136\/bmjopen-2020-040691","volume":"10","author":"Q Liu","year":"2020","unstructured":"Liu Q, Luo X, Peng L, Yi L, Wan X, Zeng X, et al. Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China. BMJ Open. 2020;10(11):e040691.","journal-title":"BMJ Open"},{"key":"14618_CR42","doi-asserted-by":"publisher","first-page":"735536","DOI":"10.3389\/fphar.2021.735536","volume":"12","author":"C Zhu","year":"2021","unstructured":"Zhu C, Xing X-x, Wu B, Liang G, Han G, Lin C-x, et al. Cost-effectiveness analysis of camrelizumab plus chemotherapy vs. chemotherapy alone as the first-line treatment in patients with IIIB\u2013IV non-squamous non-small cell lung cancer (NSCLC) without EGFR and ALK alteration from a perspective of health-care system in China. Front Pharmacol. 2021;12:735536.","journal-title":"Front Pharmacol"},{"issue":"3","key":"14618_CR43","doi-asserted-by":"publisher","first-page":"e32530","DOI":"10.1371\/journal.pone.0032530","volume":"7","author":"B Wu","year":"2012","unstructured":"Wu B, Dong B, Xu Y, Zhang Q, Shen J, Chen H, et al. Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource\u2013limited setting. PLoS ONE. 2012;7(3):e32530.","journal-title":"PLoS ONE"},{"key":"14618_CR44","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2147\/CEOR.S82194","volume":"7","author":"G Dranitsaris","year":"2015","unstructured":"Dranitsaris G, Yu B, King J, Kaura S, Zhang A. Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective. Clinicoecon Outcomes Res. 2015;7:249\u201356.","journal-title":"Clinicoecon Outcomes Res"},{"key":"14618_CR45","doi-asserted-by":"publisher","first-page":"1049947","DOI":"10.3389\/fpubh.2023.1049947","volume":"11","author":"M Zhan","year":"2023","unstructured":"Zhan M, Huang Z, Xu T, Xu X, Zheng H, Wu F. Cost-effectiveness analysis of trastuzumab deruxtecan in patients with HER2-low advanced breast cancer based on DESTINY-Breast04. Front Public Health. 2023;11:1049947.","journal-title":"Front Public Health"},{"key":"14618_CR46","doi-asserted-by":"publisher","first-page":"924126","DOI":"10.3389\/fphar.2022.924126","volume":"13","author":"J Yang","year":"2022","unstructured":"Yang J, Han J, Zhang Y, Muhetaer M, Chen N, Yan X. Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer. Front Pharmacol. 2022;13:924126.","journal-title":"Front Pharmacol"},{"issue":"1","key":"14618_CR47","first-page":"47","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4(1):47\u201353.","journal-title":"J Natl Cancer Cent"},{"issue":"3","key":"14618_CR48","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"14618_CR49","first-page":"1","volume":"2","author":"R Zheng","year":"2022","unstructured":"Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2016. J Natl Cancer Cent. 2022;2(1):1\u20139.","journal-title":"J Natl Cancer Cent"},{"issue":"11","key":"14618_CR50","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/S1470-2045(17)30604-6","volume":"18","author":"T Doi","year":"2017","unstructured":"Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody\u2013drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017;18(11):1512\u201322.","journal-title":"Lancet Oncol"},{"issue":"4","key":"14618_CR51","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s40259-019-00359-0","volume":"33","author":"SM Lee","year":"2019","unstructured":"Lee SM, Jung JH, Suh D, Jung YS, Yoo SL, Kim DW, et al. Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries. BioDrugs. 2019;33(4):423\u201336.","journal-title":"BioDrugs"},{"issue":"11","key":"14618_CR52","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s40261-022-01197-9","volume":"42","author":"Q Chai","year":"2022","unstructured":"Chai Q, Wen H, Lang Y, Zhang L, Song Y, Liu X. Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China. Clin Drug Investig. 2022;42(11):937\u201347.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"14618_CR53","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1186\/s12913-019-4715-8","volume":"19","author":"AJ Genuino","year":"2019","unstructured":"Genuino AJ, Chaikledkaew U, Guerrero AM, Reungwetwattana T, Thakkinstian A. Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines. BMC Health Serv Res. 2019;19(1):874.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"14618_CR54","doi-asserted-by":"publisher","first-page":"16736","DOI":"10.1038\/s41598-024-67598-2","volume":"14","author":"ADM Gunasekara","year":"2024","unstructured":"Gunasekara ADM, Youngkong S, Anothaisintawee T, Dejthevaporn T, Fernandopulle R, Chaikledkaew U. Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka. Sci Rep. 2024;14(1):16736.","journal-title":"Sci Rep"},{"issue":"1","key":"14618_CR55","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s40545-022-00493-1","volume":"15","author":"G Mohammadnezhad","year":"2022","unstructured":"Mohammadnezhad G, Sattarpour M, Moradi N. Budget impact analysis of breast cancer medications: a systematic review. J Pharm Policy Pract. 2022;15(1):105.","journal-title":"J Pharm Policy Pract"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-026-14618-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14618-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14618-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:02:32Z","timestamp":1783645352000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12913-026-14618-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["14618"],"URL":"https:\/\/doi.org\/10.1186\/s12913-026-14618-8","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"9 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"939"}}